Paul Tudor Jones's RARE Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 53,517 shares of Ultragenyx Pharmaceutical Inc. (RARE) worth $1.12 M, representing 0.00% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in RARE, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 40,101 shares. Largest reduction occurred in Q4 2024, reducing 54,496 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Ultragenyx Pharmaceutical (RARE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ultragenyx Pharmaceutical (RARE) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +40,101 | Add 298.90% | 53,517 | $20.95 |
| Q4 2025 | -45,862 | Reduce 77.37% | 13,416 | $23.00 |
| Q3 2025 | +6,139 | Add 11.55% | 59,278 | $30.08 |
| Q2 2025 | +30,665 | Add 136.45% | 53,139 | $36.36 |
| Q1 2025 | +22,474 | New Buy | 22,474 | $36.21 |
| Q4 2024 | -54,496 | Sold Out | 0 | $0.00 |
| Q3 2024 | +19,933 | Add 57.67% | 54,496 | $55.55 |
| Q2 2024 | +34,563 | New Buy | 34,563 | $41.10 |
| Q3 2023 | -36,919 | Sold Out | 0 | $0.00 |
| Q2 2023 | -548 | Reduce 1.46% | 36,919 | $46.13 |
| Q1 2023 | +37,467 | New Buy | 37,467 | $0.04 |
| Q4 2022 | -35,729 | Sold Out | 0 | $0.00 |
| Q3 2022 | +19,338 | Add 117.98% | 35,729 | $41.42 |
| Q2 2022 | +16,391 | New Buy | 16,391 | $59.67 |
| Q1 2022 | -4,430 | Sold Out | 0 | $0.00 |
| Q4 2021 | -31,359 | Reduce 87.62% | 4,430 | $84.20 |
| Q3 2021 | +19,932 | Add 125.70% | 35,789 | $90.20 |
| Q2 2021 | +15,857 | New Buy | 15,857 | $95.35 |
| Q1 2021 | -17,712 | Sold Out | 0 | $0.00 |
| Q4 2020 | +1,727 | Add 10.80% | 17,712 | $138.44 |
| Q3 2020 | +5,318 | Add 49.85% | 15,985 | $82.20 |
| Q2 2020 | +10,667 | New Buy | 10,667 | $78.19 |
| Q4 2019 | -14,214 | Sold Out | 0 | $0.00 |
| Q3 2019 | +14,214 | New Buy | 14,214 | $42.77 |
| Q2 2017 | -6,343 | Sold Out | 0 | $0.00 |
| Q1 2017 | +6,343 | New Buy | 6,343 | $67.79 |
| Q4 2015 | -2,441 | Sold Out | 0 | $0.00 |
| Q3 2015 | +2,441 | New Buy | 2,441 | $96.27 |
Paul Tudor Jones's Ultragenyx Pharmaceutical Investment FAQs
Paul Tudor Jones first purchased Ultragenyx Pharmaceutical Inc. (RARE) in Q3 2015, acquiring 2,441 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Ultragenyx Pharmaceutical Inc. (RARE) for 28 quarters since Q3 2015.
Paul Tudor Jones's largest addition to Ultragenyx Pharmaceutical Inc. (RARE) was in Q1 2026, adding 53,517 shares worth $1.12 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 53,517 shares of Ultragenyx Pharmaceutical Inc. (RARE), valued at approximately $1.12 M.
As of the Q1 2026 filing, Ultragenyx Pharmaceutical Inc. (RARE) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Ultragenyx Pharmaceutical Inc. (RARE) was 59,278 shares, as reported at the end of Q3 2025.